ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Semin Arthritis Rheum · 2026-04-21

Meta-analysis of 7 observational studies (21,244 patients with rheumatoid arthritis): selective JAK1 inhibitors were associated with lower discontinuation than pan-JAK inhibitors (HR 0.72), mainly for lack of efficacy (HR 0.68); adverse-event and infection stops were similar.

Meta-analysisn = 21,244
Lee et al. Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence
Rheumatology · Ann Rheum Dis · 2026-04-15

RCT in 492 patients with rheumatoid arthritis after failure of one TNF inhibitor: switching to upadacitinib achieved DAS28-CRP ≤3.2 at 12 weeks more often than adalimumab (43.3% vs 22.4%; P<.0001); HAQ-DI did not differ. Safety was comparable.

RCTn = 492 patients
Mysler et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study
Gastroenterology · J Crohns Colitis · 2026-01-09

Exploratory post hoc analysis of phase 2b/3 trials (induction: 1,021 Crohn's, 1,097 UC patients): upadacitinib benefit vs placebo was consistent across CV risk, prior treatment failure and age subgroups; herpes zoster and serious infections were numerically higher in Crohn's.

Secondary analysisn = 2,118
Vermeire et al. Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.